Although the data showed that CRC patients with KRAS mutations had a higher risk of liver metastasis, the difference was not statistically significant, and the risk of liver metastasis in patients with BRAF mutations was lower than that in patients with Wt BRAF. This evidence concerns the gene KRAS and colorectal carcinoma.